This CPB has been revised to state that Lumizyme is considered medically necessary for individuals with Pompe disease. (The previous version of the CPB limited coverage of Lumizyme to individuals 8 years of age and older with late-onset Pompe disease.) This CPB is revised to state that eliglustat (Cerdelga) is considered medically necessary for adults with type 1 Gaucher disease who are CYP2D6 extensive metabolizers, intermediate metabolizers, or poor metabolizers, when criteria are met.